Expert Opinion on Pharmacotherapy最新文献

Pharmacotherapeutic options for coronary thrombosis treatment: where are we today?

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-04 DOI: 10.1080/14656566.2025.2450353

Mohammed Ejaz Faizur Rahman, Vidun Wedagedera, William Ae Parker, Robert F Storey

{"title":"Pharmacotherapeutic options for coronary thrombosis treatment: where are we today?","authors":"Mohammed Ejaz Faizur Rahman, Vidun Wedagedera, William Ae Parker, Robert F Storey","doi":"10.1080/14656566.2025.2450353","DOIUrl":"https://doi.org/10.1080/14656566.2025.2450353","url":null,"abstract":"Introduction: Advances in pharmacotherapy for coronary thrombosis treatment and prevention have transformed the clinical outcomes of patients with coronary artery disease but increased the complexity of therapeutic decision-making. Improvements in percutaneous coronary intervention techniques and stent design have reduced the incidence of thrombotic complications, which consequently has increased the challenge of adequately powering clinical trials of novel antithrombotic strategies for efficacy outcomes. Knowledge of the pathophysiology of coronary thrombosis and the characteristics of antithrombotic drugs can help with therapeutic decisions.Areas covered: This review covers the pathophysiology of coronary thrombosis and the mechanisms of action of drugs developed for its treatment, provides an overview of the key issues in decision-making, and highlights key areas for further work in order to guide clinicians on how to individualize risk management and address gaps in the evidence base.Expert opinion: Individualisation of antithrombotic therapy regimens has become a vital part of optimizing risk management in people with coronary thrombosis. A critical appraisal of the strengths and limitations of available drugs and the evidence supporting the use of different antithrombotic combinations is intended to provide direction to clinicians and point the way toward further improvements in pharmacotherapy for coronary thrombosis treatment and prevention.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on emerging pharmacological treatments for meibomian gland dysfunction.

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-04 DOI: 10.1080/14656566.2025.2450360

Giulia Coco, Giuseppe Giannaccare

{"title":"An update on emerging pharmacological treatments for meibomian gland dysfunction.","authors":"Giulia Coco, Giuseppe Giannaccare","doi":"10.1080/14656566.2025.2450360","DOIUrl":"https://doi.org/10.1080/14656566.2025.2450360","url":null,"abstract":"Introduction: Meibomian Gland Dysfunction (MGD) represents the most common cause of dry eye disease (DED). Traditional treatments mainly rely on heating and liquifying the meibum to favor its expression. However, recent knowledge advances have led to the development of novel therapies specifically designed for patients with MGD.Areas covered: Literature search was conducted on current and novel treatments for MGD. Conventional treatment strategies, non-pharmacological approved device-based therapies, approved dry eye therapies and both recently approved and emerging pharmacological treatments specifically designed to address MGD are discussed.Expert opinion: The better understanding of MGD and DED pathophysiology has allowed to develop drugs able to target the primary mechanisms of the disease. Miebo has been the first FDA approved drug for patients with DED associated with MGD and its ability to reduce the tear film layer evaporation rate and the minimal impact on the quality of vision are important innovations. Great expectations also accompany the phase 3 study of AZR-MD-001, understood to be a keratolytic and lipogenic agent able to improve meibum quantity and quality. The chance to specifically target MGD represents an important step forward and will allow more tailored treatment for each type of ocular surface disease.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New pharmacotherapeutic strategies for drug-resistant Candida infections: a review. 耐药性念珠菌感染的新药物治疗策略：综述。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-02 DOI: 10.1080/14656566.2024.2433605

Jesse Raposa, Jose A Vazquez

{"title":"New pharmacotherapeutic strategies for drug-resistant Candida infections: a review.","authors":"Jesse Raposa, Jose A Vazquez","doi":"10.1080/14656566.2024.2433605","DOIUrl":"10.1080/14656566.2024.2433605","url":null,"abstract":"Introduction: Candida species produce a wide array of infections ranging from mucocutaneous to systemic infections. Candida albicans remains the most common species identified; however, the non-albicans Candida species have continued to increase as the diagnosis and therapeutic regimens have progressed.Areas covered: This review with discussion of the various Candida species, especially the non-albicans species, some of the important mechanisms of resistance, and newer in vitro and clinical studies describing the recent and novel antifungal options such as rezafungin, ibrexafungerp, and oteseconazole, along with a novel antifungal, fosmanogepix.Expert opinion: Initial antifungal therapy is frequently obsolete due to the expansion of antifungal resistance. This is especially true with C. glabrata, C. krusei, and most recently with C. auris. The newer and novel antifungals discussed here will add valuable tools to our antifungal armamentarium to be able to appropriately and adequately treat and manage these difficult infections. Each of the antifungals has unique and novel properties that will expand the arsenal useful to treat these fungal infections in the years to come.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.5,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments.

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-06 DOI: 10.1080/14656566.2024.2438322

Sy Duong-Quy, Cong Nguyen Hai, Tuan Huynh-Anh, Vinh Nguyen-Nhu

{"title":"Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments.","authors":"Sy Duong-Quy, Cong Nguyen Hai, Tuan Huynh-Anh, Vinh Nguyen-Nhu","doi":"10.1080/14656566.2024.2438322","DOIUrl":"10.1080/14656566.2024.2438322","url":null,"abstract":"Introduction: Pulmonary fibrosis (PF) post-COVID-19 has been identified as an important complication of Long-COVID, especially in patients with severe respiratory symptoms. High-resolution computed tomography (HRCT) is the main tool for detecting fibrotic lesions in patients with PF post-COVID-19.Areas covered: We conducted a systematic review with the following objectives: (1) to summarize the incidence and disease burden of post‑COVID‑19 pulmonary fibrosis, (2) to provide information on available therapies and drugs for its management, (3) to comprehensively evaluate the initial treatment efficacy of these drugs, and (4) to identify the limitations and challenges associated with current treatment approaches.Expert opinion: Cutting-edge treatments for PF post-COVID-19 are focused on the complex and multifactorial nature of the disease progreession during Long COVID, which involves chronic inflammation, fibroblast activation, and excessive extracellular matrix deposition leading to stiffening and fibrosis of lung tissue. While traditional antifibrotic drugs with nintedanid and pirfenidone are being used, novel therapies with anti-interleukines, mesenchymal stem cells, and Rho-kinase inhibitors promise the new treatment approaches for patients with PF post-COVID-19. Further research and clinical trials are needed to determine the most effective strategies for managing this complex condition, with the goal of improving patient outcomes and quality of life.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"75-84"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Traditional, alternative, and emerging therapeutics for focal segmental glomerulosclerosis.

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 DOI: 10.1080/14656566.2024.2446621

Silvia Di Carlo, Elisa Longhitano, Claudia Spinella, Veronica Maressa, Chiara Casuscelli, Luigi Peritore, Domenico Santoro

{"title":"Traditional, alternative, and emerging therapeutics for focal segmental glomerulosclerosis.","authors":"Silvia Di Carlo, Elisa Longhitano, Claudia Spinella, Veronica Maressa, Chiara Casuscelli, Luigi Peritore, Domenico Santoro","doi":"10.1080/14656566.2024.2446621","DOIUrl":"https://doi.org/10.1080/14656566.2024.2446621","url":null,"abstract":"Introduction: Segmental focal glomerulosclerosis is a histological lesion characterized by podocyte damage. It may be a primary disease linked to an unknown circulating factor, secondary to viral infections, drug toxicity, or a disadaptive response to the loss of nephrons, or it may depend on gene mutations or have an indeterminate cause. The treatment of the primary form involves immunosuppressors. Additional pharmacotherapies for residual proteinuria are used, and emerging therapies are being studied to target other pathological pathways.Areas covered: This paper covers the treatment of FSGS, focusing on traditional and emerging therapeutic strategies. It is based on the KDIGO 2021 guidelines and supplemented by a literature search conducted on PubMed.Expert opinion: Treating FSGS is challenging due to its heterogeneity. Immunosuppression is adequate for primary FSGS but harmful in genetic or secondary forms. Key strategies include targeting the underlying cause and using agents that affect renal hemodynamics. Antifibrotic drugs can help slow kidney damage by addressing chronic inflammation and fibrosis. Alongside pharmacological treatments, managing blood pressure and restricting dietary salt are crucial. Finally, personalized treatment requires stratifying patients based on clinical, genetic, and histological data to improve clinical trial design and outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in pharmacotherapy for the treatment of peritoneal metastases from colorectal cancer. 治疗结直肠癌腹膜转移的药物疗法进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-03 DOI: 10.1080/14656566.2024.2435946

Janson Kappen, Omar Abdel-Rahman

引用次数: 0

Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease.

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-16 DOI: 10.1080/14656566.2024.2441328

Davide Salera, Antonio Bellasi, Lucia Del Vecchio, Francesco Locatelli

{"title":"Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease.","authors":"Davide Salera, Antonio Bellasi, Lucia Del Vecchio, Francesco Locatelli","doi":"10.1080/14656566.2024.2441328","DOIUrl":"10.1080/14656566.2024.2441328","url":null,"abstract":"Introduction: Hyperphosphatemia in advanced CKD often accompanies high PTH and FGF23 levels, impaired bone mineralization, ectopic calcifications, and increased cardiovascular risks. Novel treatments are now available to lower serum phosphorus effectively. However, safety, tolerability, and patient adherence must be evaluated to determine the best therapeutic option for hyperphosphatemia.Areas covered: This review examines available treatment strategies for hyperphosphatemia in CKD patients and new emerging treatments, emphasizing the latest inhibitors of active phosphate absorption.Expert opinion: Despite the numerous compounds available, managing hyperphosphatemia in CKD remains challenging. While many phosphate binders exist, they often have limitations and side effects. Aluminum carries significant toxicity risks. Calcium-based binders are effective but can cause hypercalcemia and vascular calcification. Lanthanum is absorbed in the gut, but its long-term tissue deposition appears clinically irrelevant. Sevelamer reduces vascular calcification but has inconclusive data and gastrointestinal side effects. Iron-based binders are effective but may cause gastrointestinal discomfort and lack long-term outcome data. New inhibitors of intestinal phosphate absorption show promise with low pill burden but need more clinical validation. Although these newer compounds might eventually improve phosphate management in CKD patients, enhancing adherence and reducing pill burden, future studies are required to elucidate the best treatment for hyperphosphatemia.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"85-100"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the editor - 'Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia'. 致编辑的信--"olezarsen，一种治疗高甘油三酯血症的肝脏导向 APOC3 ASO疗法"。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-11-21 DOI: 10.1080/14656566.2024.2432487

Melvin Khee Shing Leow

引用次数: 0

Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review.

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-06 DOI: 10.1080/14656566.2024.2437525

Ali A El-Solh, Erin Gould, Keziah Aibangbee, Tanya Jimerson, Rebecca Hartling

{"title":"Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review.","authors":"Ali A El-Solh, Erin Gould, Keziah Aibangbee, Tanya Jimerson, Rebecca Hartling","doi":"10.1080/14656566.2024.2437525","DOIUrl":"10.1080/14656566.2024.2437525","url":null,"abstract":"Introduction: Traditionally, obstructive sleep apnea (OSA) management has focused on continuous positive airway pressure therapy, oral appliances, and in some cases, surgical interventions. However, these treatments do not directly address the underlying metabolic issues contributing to OSA. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for type 2 diabetes management, have demonstrated substantial efficacy in promoting weight.Areas covered: This review aims to summarize the potential impact of liraglutide, semaglutide, and tirzepatide in managing obese patients with OSA.Expert opinion: The introduction of GLP-1 RAs has gained attention not only for their ability to produce significant and sustained weight loss but also for their potential to improve OSA symptoms by reducing fat deposition around the upper airway and decreasing systemic inflammation. Emerging clinical trials suggest that GLP-1 RAs may enhance traditional OSA treatments, offering an integrated approach targeting the root cause of obesity in OSA. Additionally, GLP-1 RAs may provide benefits for other obesity-related comorbidities, including hypertension and cardiovascular disease, which are commonly associated with OSA. The future integration of GLP-1 RAs into OSA treatment protocols could mark a paradigm shift toward more comprehensive management strategies, ultimately improving patient outcomes in this complex patient population.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"51-62"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the pharmacotherapy of gout.

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-01-01 Epub Date: 2024-12-18 DOI: 10.1080/14656566.2024.2442028

Jack Shi Jie Yuan, Anush Shashidhara, Aman Sutaria, Syed Haider Tahir, Hasan Tahir

{"title":"An update on the pharmacotherapy of gout.","authors":"Jack Shi Jie Yuan, Anush Shashidhara, Aman Sutaria, Syed Haider Tahir, Hasan Tahir","doi":"10.1080/14656566.2024.2442028","DOIUrl":"10.1080/14656566.2024.2442028","url":null,"abstract":"Introduction: Gout is a common form of acute inflammatory arthritis caused by the deposition of monosodium urate crystals within synovium of joints. This leads to severe pain, reducing quality of life for patients with this condition.Areas covered: This review summarizes the treatment of both acute flares of gout and urate-lowering therapy based on guidance from various major international societies. We have also covered new emerging therapies that have not yet reached clinical practice.Expert opinion: Standard pharmacotherapies for gout flares include the options of colchicine, NSAIDs and oral or intramuscular corticosteroids, with IL-1 inhibitors newly established as an option for flare refractory to standard therapies. Urate-lowering therapies aim to prevent gout flares, with an emphasis on treat-to-target strategy; the escalation of therapies until the target serum uric acid is reached. Initial treatments include allopurinol and febuxostat, with uricosuric agents, probenecid, sulfinpyrazone and benzbromarone, as adjuncts. There are also emerging therapies in development. However, there is increasing personalization of treatment, adjusting pharmacotherapy depending on comorbidities, such as chronic kidney disease and ischemic heart disease, as well as patient preference.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"101-109"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0